Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor

British Journal of Dermatology

Volumn 147, Issue 3, 2002, Pages 598-601

  Van Doorn, R ^a   Kirtschig, G ^a   Scheffer, E ^a   Stoof, T J ^a   Giaccone, G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acneiform eruption; Cutaneous adverse effects; Epidermal growth factor receptor; ZD1839 (Iressa)

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; MINOCYCLINE; RETINOIC ACID;

ACNE; ADULT; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; ERYTHEMA; FEMALE; FOLLICULITIS; HAIR DISEASE; HAIR GROWTH; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PAPULAR SKIN DISEASE; PARAKERATOSIS; PRIORITY JOURNAL; PUSTULE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ACNEIFORM ERUPTIONS; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0036051312     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2002.04864.x     Document Type: Article

References (16)

1. ZD1839 ('Iressa') as an anticancer agent
2. ZD 1839 'Iressa'
3. New therapeutic agents targeting the epidermal growth factor receptor
4. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
5. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
6. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC)
7. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
8. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors
9. TM), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGF-TK): Evidence of good tolerability and activity
10. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages
11. The EGF receptor, an essential regulator of multiple epidermal functions
12. Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes
13. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation
14. Effects of EGF on the morphology and patterns of DNA synthesis in isolated human hair follicles
15. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure
16. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development